ArticleBritish journal of cancer1998
Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells.
Article in British journal of cancer, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- Obesogens in Prostate Cancer: An Endocrine and Metabolic Threat.Current obesity reports · 2026Review
- Inflammation impacts androgen receptor signaling in basal prostate stem cells through interleukin 1 receptor antagonist.Communications biology · 2024Article
- Inflammation Impacts Androgen Receptor Signaling in Basal Prostate Stem Cells Through Interleukin 1 Receptor Antagonist.Research square · 2023Article
- Macrophage IL-1β contributes to tumorigenesis through paracrine AIM2 inflammasome activation in the tumor microenvironment.Frontiers in immunology · 2023Article
- Review
- Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer.Cancers · 2021Review
- Interleukin-1β and Cancer.Cancers · 2020Review
- Gas Plasma-Treated Prostate Cancer Cells Augment Myeloid Cell Activity and Cytotoxicity.Antioxidants (Basel, Switzerland) · 2020Article
- A Role of the Heme Degradation Pathway in Shaping Prostate Inflammatory Responses and Lipid Metabolism.The American journal of pathology · 2020Article
- RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.The Prostate · 2020Article
- Article
- Structural and functional abnormalities of penile cavernous endothelial cells result in erectile dysfunction at experimental autoimmune prostatitis rat.Journal of inflammation (London, England) · 2019Article
- Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells.Cancer medicine · 2018Article
- Identification of an IL-1-induced gene expression pattern in ARThe Prostate · 2018Article
- IL-1β induces p62/SQSTM1 and represses androgen receptor expression in prostate cancer cells.Journal of cellular biochemistry · 2014Article
- Article
- [Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy approaches].Der Urologe. Ausg. A · 2008Review
- Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.International journal of cancer · 2007Article
- Role of desumoylation in the development of prostate cancer.Neoplasia (New York, N.Y.) · 2006Review
- Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells.British journal of cancer · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proliferative and secretory responses in androgen-sensitive prostate cancer LNCaP cells are regulated by steroid and peptide hormones and by differentiation-promoting substances. In the present study, we evaluated whether peripheral blood monocytes that exhibit anti-tumour activity in haematopoietic and solid tumours influence growth and secretion in the LNCaP cell line. For this purpose, LNCaP cells were incubated with monocyte-conditioned medium (MCM), and proliferation as well as expression of androgen receptor (AR) and secretion of prostate-specific antigen (PSA) were assessed. Conditioned medium from monocytes reduced proliferation in a dose-dependent manner. Incubation with 40% MCM caused a 50% reduction in cell proliferation. AR protein decreased by 70% and PSA levels in supernatants from LNCaP cells were reduced by approximately 80% following treatment with MCM. We focused on the contribution of two major products of activated monocytes, prostaglandin E2 and interleukin 1beta (IL-1beta), to the MCM modulatory action. LNCaP cells treated with prostaglandin E2 showed neither a reduction in proliferation nor a down-regulation of AR and PSA levels. The effects of MCM on cellular proliferation, AR protein and PSA secretion were abolished by pretreatment of MCM with a neutralizing anti-IL-1beta antibody. In addition, recombinant IL-1beta was able to replace MCM for the inhibition of proliferation and down-regulation of AR and PSA proteins. LNCaP cells were shown to express the IL-1beta receptor type 1, which transduces IL-1beta signal. Our findings reveal that monocyte-derived IL-1beta inhibits the proliferation of androgen-responsive prostate tumour cells and reduces AR and PSA levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.